Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 5;12(3):161.
doi: 10.3390/toxins12030161.

Cardiac Remodeling in Chronic Kidney Disease

Affiliations
Review

Cardiac Remodeling in Chronic Kidney Disease

Nadine Kaesler et al. Toxins (Basel). .

Abstract

Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality of life and survival. Current treatment options are highly inadequate. As kidney function declines, numerous metabolic pathways are disturbed. Kidney and heart functions are highly connected by organ crosstalk. Among others, altered volume and pressure status, ischemia, accelerated atherosclerosis and arteriosclerosis, disturbed mineral metabolism, renal anemia, activation of the renin-angiotensin system, uremic toxins, oxidative stress and upregulation of cytokines stress the sensitive interplay between different cardiac cell types. The fatal consequences are left-ventricular hypertrophy, fibrosis and capillary rarefaction, which lead to systolic and/or diastolic left-ventricular failure. Furthermore, fibrosis triggers electric instability and sudden cardiac death. This review focuses on established and potential pathophysiological cardiorenal crosstalk mechanisms that drive uremia-induced senescence and disease progression, including potential known targets and animal models that might help us to better understand the disease and to identify novel therapeutics.

Keywords: cardiac fibrosis; cardiorenal syndrome; chronic kidney disease; heart failure; left-ventricular hypertrophy; organ crosstalk; uremia; uremic cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Luyckx V.A., Tonelli M., Stanifer J.W. The global burden of kidney disease and the sustainable development goals. Bull. World Health Organ. 2018;96:414–422. doi: 10.2471/BLT.17.206441. - DOI - PMC - PubMed
    1. Wang H., Naghavi M., Allen C., Barber R.M., Bhutta Z.A., Carter A., Coggeshall M. GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544. doi: 10.1016/S0140-6736(16)31012-1. - DOI - PMC - PubMed
    1. Bikbov B., Perico N., Remuzzi G. On behalf of the GBD Genitourinary Diseases Expert Group Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. Nephron. 2018;139:313–318. doi: 10.1159/000489897. - DOI - PubMed
    1. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., Richard Hobbs F.D. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0158765. doi: 10.1371/journal.pone.0158765. - DOI - PMC - PubMed
    1. Shamseddin M.K., Khaled Shamseddin M., Parfrey P.S. Sudden cardiac death in chronic kidney disease: Epidemiology and prevention. Nat. Rev. Nephrol. 2011;7:145–154. doi: 10.1038/nrneph.2010.191. - DOI - PubMed

Publication types

MeSH terms